Drugs / INCA035784
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07008118 | Oct 2025 → Mar 2028 expected | myeloproliferative neoplasm | Incyte Corporation | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | Incyte Corporation | Results Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress incyte.com ↗
Preclinical Evaluation of INCA035784, a Novel T-Cell–Redirecting Antibody for the Treatment of MutCALR-Driven Myeloproliferative Neoplasms (MPNs) |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | Incyte Corporation | Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress incyte.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCA035784 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07008118 ↗ |